Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Zenas BioPharma, Inc. due to allegations of violations of federal securities laws related to misleading statements about the company's financial status and operational funding [3][5]. Group 1: Legal Investigation - The firm is reminding investors of the June 16, 2025 deadline to seek the role of lead plaintiff in a federal securities class action against Zenas [3]. - The complaint alleges that Zenas BioPharma overstated its ability to fund operations with existing cash and expected IPO proceeds, leading to materially false and misleading public statements [5]. Group 2: Investor Communication - Faruqi & Faruqi encourages investors who suffered losses in Zenas to contact them directly to discuss their legal options [1]. - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding Zenas' conduct [7].
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma